| Document |
Document Title |
|
WO/2013/070236 |
The present invention relates to compositions and methods for treatment of internal and/or external hemorrhoids, wherein the treatment includes topically administering to a subject a composition comprising from 0.3% to 0.7% of S-2'- [2-(...
|
|
WO/2013/068504 |
The present invention relates to the use of apotransferrin for the preparation of a medicament for the treatment of brain stroke. Particularly the invention relates to the use of apotransferrin for the preparation of a medicament for the...
|
|
WO/2013/070734 |
Provided herein is a new method to isolate and expand cardiac progenitor/stem cells from a placenta, which produces a cell population enriched in multipotent functional progenitor/stem cells. Cardiac progenitor/stem cells isolated by thi...
|
|
WO/2013/068306 |
The invention relates to a compound of formula (I), wherein A, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament as agonists of the cannabinoid receptor 2.
|
|
WO/2013/068875 |
Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
|
|
WO/2013/067579 |
Disclosed are methods and compositions for modulating adiposity-related conditions, which utilize inhibitors of phospholipase A2, and more particularly phospholipase A2 Group IIa (PLA2G2A). Representative adiposity-related conditions inc...
|
|
WO/2013/070048 |
The present invention relates to a pharmaceutical composition for preventing or treating ischaemic heart disease comprising, as an active ingredient, an inhibitor that inhibits AGE-albumin synthesis or secretion in mononuclear phagocyte ...
|
|
WO/2013/069661 |
The present invention addresses the problem of providing a vascular progenitor cell sheet derived from induced pluripotent stem cells, which has the strength to tolerate practical applications and exhibits a high treatment effect. This v...
|
|
WO/2013/070657 |
The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof that are useful in methods of treatment and alleviation of diseases and disorders of the heart, brain, kidney...
|
|
WO/2013/068600 |
The present invention relates to a medicament for the treatment of cardiac disease, especially to a medicament suitable for the treatment of myocardial disease involving myocyte hypertrophy, especially fibroblast-derived cardiac hypertro...
|
|
WO/2013/065712 |
[Problem] To provide a compound having sEH inhibitory activity and to provide a pharmaceutical that actualizes a therapeutic effect based on the mechanism against hypertension and other such cardiovascular diseases. [Solution] The invent...
|
|
WO/2013/064672 |
The invention relates to oxazaphosphorines of formula (I), wherein R1 and R2 are 2-chloroethyl or H and R3 is 2-sulfonatoethylthio or H, for treating diseases that are caused or maintained by the tolerogen indolamine-2,3-dioxygenase (IDO...
|
|
WO/2013/064307 |
Ivabradine hydrochloride Form IV, its pharmaceutical composition, process for its preparation, and its use as therapeutically active ingredient.
|
|
WO/2013/067163 |
In one aspect, the invention relates to compounds having the formula: (I) where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. I...
|
|
WO/2013/064029 |
Provided in the present invention are a benzoylurea derivative of formula (I) with anticancer activity or the pharmaceutically acceptable salt or prodrug thereof, and the preparation of such a derivative and the use thereof in preparing ...
|
|
WO/2013/064031 |
Disclosed are an N-benzylaniline derivative and uses thereof. The derivative is a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound has an action of protecting against cerebral ischemia/reperfu...
|
|
WO/2013/066869 |
Compounds of Formula (I) and pharmaceutically acceptable salts thereof in which X1, X2, X3, L, R3, R4, R5, R7 and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of d...
|
|
WO/2013/063889 |
Provided is the use of multiflora glycoside in preparing an anti-hypoxic drug. A full body and cell level hypoxia model indicates that multiflora glycoside can significantly increase the survival time of a mouse with asphyxiant hypoxia, ...
|
|
WO/2013/064508 |
The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicame...
|
|
WO/2013/067425 |
[00256] 2-((3-(4-cyanonaphthalen-l-yl)pyridin-4-yl)thio)-2-methylpro
panoic acid is useful in the modulation of blood or serum uric acid levels. In some embodiments, 2-((3-(4- cyanonaphthalen-l-yl)pyridin-4-yl)thio)-2-methylpropanoic aci...
|
|
WO/2013/067260 |
Bicyclic piperazine compounds of Formula (I) are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediat...
|
|
WO/2013/067248 |
The invention relates to benzoxazines useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treat...
|
|
WO/2013/062332 |
The present invention discloses a vascular anti-aging composition including a compound of Chemical formula 1, a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient.
|
|
WO/2013/063217 |
Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atheroscl...
|
|
WO/2013/060887 |
A peptide of the formula R1-NH-HAEGTFTSDVSSYLEGQAAKEFIAWLVK-CONR2R3 wherein R = H or an organic compound comprising from 1 to 10 carbon atoms and R2 R3 = independently H or an alkyl group of 1 to 4 carbon atoms; or certain analogues of s...
|
|
WO/2013/060636 |
The present invention relates to 1 H-pyrazolo[3,4-b]pyridine compounds of the formula (I) in which R1, R2, R3 and R4 are defined as indicated below. The compounds of the formula I are protein kinase C (PKC) inhibitors, and are useful for...
|
|
WO/2013/062027 |
The invention according to the present application provides a therapeutic or prophylactic agent for diseases including mood disorders, anxiety disorders, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eatin...
|
|
WO/2013/060303 |
Provided are polypeptides for inhibiting angiogenic activity, the source of said polypeptides being placental growth factor-1. Also provided are derivatives of the polypeptides, nucleic acid molecules for encoding same, a pharmaceutical ...
|
|
WO/2013/063331 |
Agents, methods, and devices for affecting nerve function are described. One embodiment of an agent includes a cardiac glycoside, an ACE inhibitor, and an NSAID. The agent may be delivered locally in a site-specific manner to a targeted ...
|
|
WO/2013/062316 |
The present invention relates to a novel use of modafinil or the derivatives thereof as a therapeutic agent for vascular diseases or KCa3.1-channel-mediated diseases. More particularly, the present invention relates to modafinil or deriv...
|
|
WO/2013/059879 |
The present invention provides pharmaceutical compositions comprising at least one relaxin polypeptide and at least one ACE inhibitor for use in the treatment of fibrosis and fibrotic diseases and in reducing or preventing the progressio...
|
|
WO/2013/060097 |
The present invention provides compounds having the structure represented by general formula I, pharmaceutically acceptable salts thereof, preparation methods therefor and a use thereof in the preparation of a medicine for the treatment ...
|
|
WO/2013/063004 |
Devices and methods for administering a therapeutic agent, comprising an implantable delivery device. Exemplary embodiments comprise a reservoir in fluid communication with a channeled member, and a solid matter therapeutic agent dispose...
|
|
WO/2013/061977 |
The present invention pertains to the compound represented by formula (I) (in the formula: X1, X2, X3, X4, X5, R5, R6, R7, R8, n, p, q, ring A, and ring B have the same meaning as the definitions described in the description) or a pharma...
|
|
WO/2013/062441 |
The invention relates to medicine, in particular to the treatment of disorders of the cerebral circulation, and relates to a pharmaceutical combination which comprises, as active ingredients, atorvastatin or a pharmaceutically acceptable...
|
|
WO/2013/062489 |
The invention is directed to a method for maintaining structure, homeostasis, repairing or treating media thinning of one or more blood vessels as well as treating atherosclerosis or ischaemic heart disease. The method comprises contacti...
|
|
WO/2013/060673 |
The present invention relates to nitric oxide donor compounds having a quinone based structure, to processes for their preparation and to their use in the treatment of pathological conditions where a deficit of NO plays an important role...
|
|
WO/2013/060751 |
The invention relates to a compound of formula (I), wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2013/057944 |
The present invention provides a novel compound represented by general formula (1), which has an activity of activating glucokinase occurring in the liver and a pancreatic β cell and is useful as a prophylactic and/or therapeutic agent ...
|
|
WO/2013/058630 |
The present invention relates to a novel use of stereocalpin A, and more particularly, to a pharmaceutical composition containing stereocalpin A for preventing or treating arteriosclerosis, and to a composition containing stereocalpin A ...
|
|
WO/2013/059702 |
Pharmaceutical formulations and methods of using thereof for the treatment and prevention of pulmonary arterial hypertension are provided. The formulations contain one or more agents to simultaneously reduce ADMA levels in a patient and ...
|
|
WO/2013/057545 |
The present invention relates to the stable acid addition salts of Bosentan that are useful for the purification of Bosentan base. In particular, the Bosentan acid addition salt is selected from Bosentan citrate and Bosentan tartrate.
|
|
WO/2013/058303 |
The present invention provides a medicinal composition capable of preventing a decrease in the blood exposure level of a third generation coxib drug, a method for preparing the composition and utilization of the same. It was discovered t...
|
|
WO/2013/057357 |
The present invention relates to methodologies for identifying treatments suitable for cardiovascular pathological conditions, with methods for determining the cardiovascular risk in a subject, with methods for monitoring the response of...
|
|
WO/2013/057650 |
The present invention relates to novel substituted imidazo[1,2-a]pyrimidine compounds of formula (I), their pharmaceutically acceptable salts, and their isomers, stereoisomers, conformers, tautomers, polymorphs, hydrates and solvates. Th...
|
|
WO/2013/057205 |
The present invention describes novel PDE5 inhibitors that contain a diazabicyclo- or diazaspiro-alkane radical. These diazabicyclo- and diazaspiro-alkane radicals can be regarded as conformationally fixed piperazine analogs, where some ...
|
|
WO/2013/058632 |
The present invention relates to a composition containing extracts of polytrichastrum alpinum for preventing or treating arteriosclerosis. More particularly, the present invention relates to a pharmaceutical composition containing, as an...
|
|
WO/2013/059194 |
The disclosed subject matter provides certain N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In partic...
|
|
WO/2013/058605 |
The present invention relates to a pharmaceutical composition comprising fluoxetine as an active ingredient for preventing or treating blood-brain barrier disorders. More particularly, it is defined that fluoxetine may inhibit expression...
|
|
WO/2013/057580 |
The invention relates to a method of treating capillary hemangiomas in a human in need thereof by topically administering an effective amount of one or more alpha-2 adrenergic receptors agonist to the site of the capillary hemangiomas on...
|
